Clinical Trials Logo

Metastatic Pancreatic Cancer clinical trials

View clinical trials related to Metastatic Pancreatic Cancer.

Filter by:

NCT ID: NCT01077986 Completed - Clinical trials for Metastatic Pancreatic Cancer

Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer

Start date: August 2009
Phase: Phase 1/Phase 2
Study type: Interventional

In this study the investigators want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with metastatic pancreatic cancer.

NCT ID: NCT01040000 Completed - Clinical trials for Metastatic Colorectal Cancer

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to standard treatments can shrink or halt the growth of cancer, and to obtain additional data to study its effect on the immune system. Safety data will also be accumulated and evaluated during this study. NPC-1C is a monoclonal antibody that recognizes a specific tumor target on certain cancers. In laboratory studies, the antibody killed tumor cells in some colon and pancreatic cancers that express the NPC-1C antigen by a process called "antibody-dependent cell cytotoxicity" or ADCC.

NCT ID: NCT01028495 Completed - Clinical trials for Metastatic Pancreatic Cancer

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Start date: May 2009
Phase: Phase 2
Study type: Interventional

To assess the safety and efficacy of a combined therapy regimen of RX-0201 plus Gemcitabine, in subjects with metastatic pancreatic cancer.

NCT ID: NCT00996333 Completed - Clinical trials for Metastatic Pancreatic Cancer

Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Start date: June 2003
Phase: Phase 2
Study type: Interventional

This study is designed to determine whether an investigational drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.

NCT ID: NCT00954525 Completed - Clinical trials for Metastatic Pancreatic Cancer

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Start date: July 2009
Phase: Phase 1
Study type: Interventional

Eligible candidates will be adults with metastatic pancreatic cancer (confirmed diagnosis with pathology reports and measurable computed tomography (CT) or magnetic resonance imaging (MRI)). Participants must not be receiving any other concurrent chemotherapy, or radiation therapy. Full inclusion/exclusion criteria are available. History and physical examination, and laboratory and imaging analyses will be done within 14 days prior to registration. The three cohorts of subjects will receive 50, 75 or 100 grams of intravenous ascorbic acid, three times per week for 8 weeks. Subjects will also have co-administration of the chemotherapy medications, gemcitabine (intravenously) and erlotinib (orally). Approximately 9 to 18 participants will be enrolled in this Phase I study.

NCT ID: NCT00922896 Completed - Clinical trials for Metastatic Pancreatic Cancer

Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

NCT ID: NCT00919282 Completed - Clinical trials for Metastatic Pancreatic Cancer

Gemcitabine (GFF) in Patients With Pancreatic Cancer

GFF
Start date: September 1997
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).

NCT ID: NCT00844649 Completed - Clinical trials for Metastatic Pancreatic Cancer

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Start date: March 1, 2009
Phase: Phase 3
Study type: Interventional

Phase III Metastatic Pancreatic Cancer

NCT ID: NCT00837031 Completed - Clinical trials for Metastatic Pancreatic Cancer

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Start date: February 2009
Phase: Phase 2
Study type: Interventional

To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.

NCT ID: NCT00786006 Completed - Clinical trials for Metastatic Pancreatic Cancer

Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The investigators are to evaluate the efficacy and safety of FOLFOX or FOLFIRI.3 combination chemotherapy as second-line salvage chemotherapy in patients with advanced pancreatic carcinoma.